Future Price to Earnings: Helius Medical Technologies, Inc. (HSDT)
Helius Medical (HSDT) is implementing advanced neuromodulators for rehabilitation, ensuring high margins through its patents. The company's expected P/E multiple reflects valuation dynamics relative to future earnings, where 182.50 is recorded as the baseline value. Market capitalization is based on the deployment of PoNS stimulators, while scaling efficiency is supported by software robots that automate clinical reporting.
Analytical breakdowns and data insights for company Helius Medical Technologies Inc. (HSDT)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- balance sheet equity data:
- debt obligations and liquidity statistics:
Debt to Equity Helius Medical|HSDT - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Helius Medical|HSDT - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Helius Medical|HSDT - Company Long-Term Liabilities|Company Short-Term Debts Helius Medical Technologies|Quick Ratio heliusmedical.com
- earnings and market ratios statistics:
HSDT - Company Profit|Projected Future Earnings Helius Medical|HSDT - Business Payback Period|Forward P/E Multiple Helius Medical|HSDT - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Helius Medical|HSDT - Operating profit EBITDA|Earnings per share for the last twelve months Helius Medical Technologies|HSDT - Earnings per share for the last twelve months|Quarterly EPS earnings growth heliusmedical.com|HSDT - Earnings per share increase in current year|Net earnings per share growth forecast for next year Helius Medical
Fundamental valuation:HSDT Helius Medical Technologies
The high scalability of Helius Medical (HSDT) neuromodulation systems through global software and hardware sales creates potential for rapid profit growth. By analyzing the company's forward P/E NTM, an investor assesses the current share price relative to projected net income, which helps determine the premium paid for future success and evaluate the business's resilience to market corrections.
Competitors of Helius Medical
Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Future Price to Earnings Regencell RGC|Axsome Corp - Future Price to Earnings|ACADIA Pharmaceuticals - Forward P/E Multiple|Market Cap to Projected Earnings xenon-pharma.com XENE|VKTX (Viking Therapeutics, Inc.) - Projected Price to Earnings|Supernus Pharmaceuticals, Inc. (SUPN) - Forward P/E Multiple|Future Price to Earnings Catalyst Pharmaceuticals Inc|Denali Corp (DNLI) - Market Cap to Projected Earnings|Projected Price to Earnings HRMY (Harmony Biosciences)|BHVN (biohavenpharma.com) - Future Price to Earnings Multiple|Future Price to Earnings Amylyx Pharmaceuticals, Inc. AMLX|TRVI - Projected Price to Earnings|Praxis Medicines - Forward P/E Multiple|Projected Price to Earnings Ratio Anavex Life Sciences Corp|CBLL: Forward P/E Multiple|Price to Future Earnings Ratio PRTA|ALEC (Alector Inc.) - Forward P/E Multiple|Annexon Biosciences (ANNX) - Market Cap to Projected Earnings|Forward P/E Multiple OMER|Projected Price to Earnings Neurogene Therapeutics NGNE|Forward P/E Multiple ACIU (AC Immune)|Forward P/E Multiple voyagertherapeutics.com VYGR|NMRA - Future Price to Earnings|SCLX: Future Price to Earnings|TVGN: Forward P/E Multiple|Alpha Cognition Inc. - Future Price to Earnings Multiple|Future Price to Earnings Cognition Therapeutics|inhibikase.com (IKT) - Market Cap to Projected Earnings|Forward P/E Multiple SAVA|assertiotx.com - Price to Future Earnings Ratio|Coya Therapeutics - Projected Price to Earnings|Market Cap to Future Earnings Ratio VTGN (VistaGen Therapeutics, Inc.)|OVID - Future Price to Earnings|ABOS (acumenpharm.com) - Price to Future Earnings Ratio|CRVO: Forward P/E Multiple|Projected Price to Earnings Ratio Alterity Therapeutics Limited (ATHE)|Projected Price to Earnings CLNN|Forward P/E Multiple PepGen Corp|Future Price to Earnings Jupiter Neurosciences Inc (JUNS)|RLMD (relmada.com) - Future Price to Earnings Multiple|Future Price to Earnings Annovis Bio ANVS|Grace Therapeutics Inc (GRCE) - Projected Price to Earnings Ratio|Firefly Neuroscience Inc - Forward P/E Multiple|Future Price to Earnings Multiple KLTO (Klotho Neurosciences Inc)|NRSN: Forward P/E Multiple|Projected Price to Earnings Ratio revivapharma.com (RVPH)|Future Price to Earnings MetaVia Inc.|Future Price to Earnings NRXS|Forward P/E Multiple PASG|Market Cap to Projected Earnings bionomics.com.au|Minerva Neurosciences - Projected Price to Earnings|Forward P/E Multiple athira.com ATHA|ADXN - Future Price to Earnings|Market Cap to Projected Earnings Alzamend Neuro, Inc. ALZN|CYCN (cyclerion.com) - Projected Price to Earnings|Protagenic Therapeutics, Inc. - Future Price to Earnings Multiple|Future Price to Earnings Pasithea Therapeutics Corp|Projected Price to Earnings Cortigent Medical (CRGT)|Forward P/E Multiple ATXI|BCLI - Projected Price to Earnings Ratio|Forward P/E Multiple CARA (Cara Therapeutics, Inc)|CHRO: Price to Future Earnings Ratio|Eliem - Forward P/E Multiple|Market Cap to Projected Earnings Intra-Cellular Therapies ITCI|LBPH: Forward P/E Multiple|Projected Price to Earnings Marinus Pharmaceuticals Inc|NKGN (NKGen) - Forward P/E Multiple|Forward P/E Multiple NeuroBo Pharma|Future Price to Earnings Sage Therapeutics, Inc. (SAGE)|Future Price to Earnings SNPX (synaptogen.com)|Forward P/E Multiple TRVN (Trevena)|Future Price to Earnings Multiple VIGL|WENA - Future Price to Earnings|Market Cap to Projected Earnings Cerevel Corp CERE
